Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
BF Haynes, K Wiehe, P Borrow, KO Saunders… - Nature Reviews …, 2023 - nature.com
After nearly four decades of research, a safe and effective HIV-1 vaccine remains elusive.
There are many reasons why the development of a potent and durable HIV-1 vaccine is …
There are many reasons why the development of a potent and durable HIV-1 vaccine is …
HIV infection: epidemiology, pathogenesis, treatment, and prevention
G Maartens, C Celum, SR Lewin - The Lancet, 2014 - thelancet.com
HIV prevalence is increasing worldwide because people on antiretroviral therapy are living
longer, although new infections decreased from 3· 3 million in 2002, to 2· 3 million in 2012 …
longer, although new infections decreased from 3· 3 million in 2002, to 2· 3 million in 2012 …
Multiple lineages of monkeypox virus detected in the United States, 2021–2022
Monkeypox is a viral zoonotic disease endemic in Central and West Africa. In May 2022,
dozens of non-endemic countries reported hundreds of monkeypox cases, most with no …
dozens of non-endemic countries reported hundreds of monkeypox cases, most with no …
SARS-CoV-2 evolution during treatment of chronic infection
The spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is
critical for virus infection through the engagement of the human ACE2 protein and is a major …
critical for virus infection through the engagement of the human ACE2 protein and is a major …
A multiclade env–gag VLP mRNA vaccine elicits tier-2 HIV-1-neutralizing antibodies and reduces the risk of heterologous SHIV infection in macaques
The development of a protective vaccine remains a top priority for the control of the HIV/AIDS
pandemic. Here, we show that a messenger RNA (mRNA) vaccine co-expressing …
pandemic. Here, we show that a messenger RNA (mRNA) vaccine co-expressing …
Brain microglia serve as a persistent HIV reservoir despite durable antiretroviral therapy
Brain microglia (MG) may serve as a human immunodeficiency virus 1 (HIV) reservoir and
ignite rebound viremia following cessation of antiretroviral therapy (ART), but they have yet …
ignite rebound viremia following cessation of antiretroviral therapy (ART), but they have yet …
Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial
B Julg, KE Stephenson, K Wagh, SC Tan, R Zash… - Nature medicine, 2022 - nature.com
HIV-1 therapy with single or dual broadly neutralizing antibodies (bNAbs) has shown viral
escape, indicating that at least a triple bNAb therapy may be needed for robust suppression …
escape, indicating that at least a triple bNAb therapy may be needed for robust suppression …
[HTML][HTML] Neutralising antibodies in Spike mediated SARS-CoV-2 adaptation
SARS-CoV-2 Spike protein is critical for virus infection via engagement of ACE2, and amino
acid variation in Spike is increasingly appreciated. Given both vaccines and therapeutics are …
acid variation in Spike is increasingly appreciated. Given both vaccines and therapeutics are …
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
Monoclonal antibody 10-1074 targets the V3 glycan supersite on the HIV-1 envelope (Env)
protein. It is among the most potent anti-HIV-1 neutralizing antibodies isolated so far. Here …
protein. It is among the most potent anti-HIV-1 neutralizing antibodies isolated so far. Here …
Effect of HIV antibody VRC01 on viral rebound after treatment interruption
KJ Bar, MC Sneller, LJ Harrison… - … England Journal of …, 2016 - Mass Medical Soc
Background The discovery of potent and broadly neutralizing antibodies (bNAbs) against
human immunodeficiency virus (HIV) has made passive immunization a potential strategy …
human immunodeficiency virus (HIV) has made passive immunization a potential strategy …